# FINAL INVESTMENT DECISION HPA FIRST PROJECT STAGE 2



#### DISCLAIMER

This investor presentation (Presentation) is dated 20 May 2024 and has been prepared by Alpha HPA Limited (ABN 79 106 879 690) (**Alpha, Alpha HPA** or **the Company**). By attending an investor presentation or briefing, or accepting, accessing or reviewing this Presentation, you acknowledge and agree to the terms set out below.

This Presentation has been prepared in relation to:

- a fully underwritten placement of new fully paid ordinary shares in Alpha (New Shares) to institutional investors in certain jurisdictions (Placement); and
- a non-underwritten offer of New Shares to eligible Alpha shareholders in Australia and New Zealand under a share purchase plan in accordance with the Corporations Act 2001 (Cth) (Corporations Act) as modified by ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (SPP).

The Placement and SPP are together the Equity Raising.

#### SUMMARY INFORMATION

This Presentation is for information purposes only and contains information in a summary form. The information in this Presentation is of a general nature and does not purport to be complete, nor does it contain all the information which a prospective investor and their professional advisers may reasonably require in evaluating a potential investment in the Company, or that would be required to be included in a prospectus, product disclosure statement or other offer document under Australian law or under the laws of any other jurisdiction. This Presentation will not be lodged with the Australian Securities and Investments Commission (ASIC) or any other foreign regulator. It should be read in conjunction with Alpha's most recent financial report and Alpha's other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which is available at www.asx.com.au. The content of this Presentation is provided as at the date of this Presentation (unless otherwise stated).

An offer booklet in respect of the SPP will be made available to eligible shareholders in Australia and New Zealand following its lodgement with ASX (Offer Booklet). Any eligible shareholder in Australia or New Zealand who wishes to participate in the SPP should carefully read and consider the Offer Booklet (in full) before deciding whether to apply for New Shares under the SPP. Eligible shareholders who wish to apply for New Shares under the SPP. Eligible shareholders who wish to apply for New Shares under the spectrum of the offer Booklet and the application form.

#### NOT FINANCIAL PRODUCT ADVICE OR OFFER

The information contained in this Presentation is not investment, tax, legal, accounting, financial or other advice and does not, and will not, form any part of any contract or commitment. It does not account for your particular needs and circumstances, including your investment objectives, financial situation, tax or other position. Any investment decision in relation to the Equity Raising or the Company should be made solely on the basis of your own independent enquiries.

#### INTERNATIONAL RESTRICTIONS

The distribution of this Presentation to jurisdictions outside Australia may be restricted by law and you must observe any such restrictions. Failure to comply with these restrictions may constitute a violation of applicable securities laws (see Appendix B: International Offer Restrictions) of this Presentation). In particular, this Presentation may not be distributed or released in the United States. By accepting this Presentation, you represent and warrant that you are entitled to receive it in accordance with the above restrictions and agree to be bound by the limitations contained herein.

This Presentation may not be released or distributed in the United States. This Presentation is not, and does not constitute, an invitation or offer of securities for subscription, purchase or sale in any jurisdiction, including the United States, in which it would be unlawful to make such an offer. The New Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act), or under the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which Alpha has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state or federal securities laws. The New Shares will not be offered or sold to the public in the United States. Refer to Appendix B: International Offer Restrictions of this Presentation for further details about international offer restrictions.

#### INVESTMENT RISK

An investment in Alpha shares is subject to known and unknown risks, some of which are beyond the control of the Company and its directors. Alpha does not guarantee any particular rate of return or financial performance, nor does it guarantee any particular tax treatment. You should have regard to the risk factors outlined in Appendix A: Key Risks of this Presentation when making your investment decision.

#### **CAUTIONARY STATEMENT**

The Definitive Feasibility Study (DFS) referred to in this Presentation has been undertaken to assess the technical and financial viability of the HPA First project. The DFS is based on the material assumptions about the availability of funding and the pricing received for Alpha. While the Company considers all of the material assumptions to be based on reasonable grounds, there is no certainty that they will prove to be correct or that the outcomes indicated by this DFS will be achieved. To achieve the range of outcomes indicated in the DFS, additional funding will be required. Investors should note that there is no certainty that the Company will be able to raise the amount of funding when needed. It is also possible that such funding may only be available on terms that may be dilutive to or otherwise affect the value of the Company's existing shares. It is also possible that the Company could pursue other 'value realisation' strategies such as a sale, partial sale or joint venture of the HPA First project. If it does, this could materially reduce the Company's proportionate ownership of the HPA First project. Given the uncertainties involved, investors should not make any investment decisions based solely on the results of the DFS.









#### FINANCIAL AND OTHER INFORMATION

All financial information in this Presentation is in Australian dollars (AUD\$ or AUD) unless otherwise stated. Any pro forma financial information of Alpha provided in this Presentation has been prepared on the basis set out, and includes certain adjustments. To the maximum extent permitted by law, the Limited Parties (as defined below) disclaim all responsibility and liability for any information provided.

Any pro forma financial information included in this Presentation has been prepared by Alpha in accordance with the measurement and recognition principles, but not the disclosure requirements, prescribed by the Australian Accounting Standards (AAS) unless stated otherwise, and has not been subject to external audit or review. In addition, any pro forma financial information in this document does not purport to be in compliance with Article 11 of Regulation S-X of the rules and regulations of the U.S. Securities and Exchange Commission, and such information does not purport to comply with Article 3-05 of Regulation S-X. Any pro forma financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Alpha's views on its, nor anyone else's, future financial position and/or performance or any scale benefits, synergies or opportunities that may be realised.

Investors should be aware that certain financial measures included in this Presentation are 'non-IFRS financial information' under ASIC Regulatory Guide 230: 'Disclosing non-IFRS financial information' published by ASIC and also 'non-GAAP financial measures' within the meaning of Regulation G under the U.S. Securities Exchange Act of 1934, as amended, and are not recognised under AAS and International Financial Reporting Standards (IFRS). Such non-IFRS financial information/non-GAAP financial measures do not have a standardised meaning prescribed by AAS or IFRS. Therefore, the non-IFRS financial information may not be comparable to similarly titled measures presented by other entities and should not be construed as an alternative to other financial information/non-GAAP financial measures these non-IFRS financial information/non-GAAP financial measures these non-IFRS financial information formation to investors in measuring the financial information formation of its business, investors must not to place undue reliance on any non-IFRS financial information/non-GAAP financial measures included in this Presentation.

Certain figures, amounts, percentages, estimates, calculations of value and fractions provided in this Presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this Presentation.

#### PAST PERFORMANCE

Past performance, including past share price performance of Alpha and pro forma financial information given in this Presentation, is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Alpha's views on its future financial performance or condition. Past performances of Alpha cannot be relied upon as an indicator of (and provides no guidance as to) the future performance of Alpha including future share price performance. Nothing contained in this Presentation, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future.

#### **FUTURE PERFORMANCE**

This Presentation contains certain forward-looking statements, which include, but are not limited to, words such as "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan", "propose", "likely", "target" and other similar expressions that are intended to identify forward-looking statements. Indications of, and guidance or outlook on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements are usually predictive in character, may be affected by inaccurate assumptions or unknown risks and uncertainties, or may differ materially from results ultimately achieved. As such, these statements should not be relied upon when making investment decisions.

Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties (included in the Appendix A: Key Risks) and other factors that are beyond the control of the Limited Parties. This includes statements about market and industry trends, which are based on interpretations of current market conditions. The Joint Lead Managers (as defined below) and their related bodies corporate (as defined in the Corporations Act) and affiliates and each of their respective officers, directors, partners, employees, agents and advisers (Joint Lead Manager Parties) have not authorised, approved or verified the forward-looking statements or any other statements or information contained in this Presentation.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Alpha's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Investors are strongly cautioned not to place undue reliance on forward-looking statements, particularly given the current economic climate and geopolitical tensions, including ongoing conflicts in Ukraine and the Middle East. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward-looking statements are based on information available to Alpha as at the date of this Presentation.

All references to time in this Presentation are to Australian Eastern Standard Time (AEST), unless otherwise indicated.

#### DISCLAIMER

Bell Potter Securities Limited and Macquarie Capital (Australia) Limited (Joint Lead Managers) are acting as joint lead managers, bookrunners and underwriters to the Placement. A summary of the key terms of the underwriting agreement between Alpha and the Joint Lead Managers are provided in Appendix C of this Presentation. Macquarie Capital (Australia) Limited is not an authorised deposit-taking institution for the purposes of the Banking Act 1959 (Commonwealth of Australia), and Macquarie Capital (Australia) Limited's obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542. Any investments are subject to investment risk including possible delays in repayment and loss of income and principal invested. Macquarie Bank Limited does not guarantee or otherwise provide assurance in respect of the obligations of Macquarie Capital (Australia) Limited.









The Joint Lead Managers, their affiliates and related bodies corporate, are full service financial institutions engaged in various activities, which may include trading, financing, corporate advisory, financial advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services, including for which they have received or may receive customary fees and expenses. The Joint Lead Managers (and/or their affiliates or related bodies corporate) have provided, and may in the future provide, financial advisory, financing services and other services to Alpha and to persons and entities with relationships with Alpha, and/or may have other interests in or relationships with Alpha and to persons and entities with relationships with Alpha, for which they received or will receive customary fees and expenses, including in relation to the Joint Lead Managers acting as joint lead manager and underwriters of the Placement. In the ordinary course of its various business activities, the Joint Lead Managers (and/or their respective affiliates and related bodies corporate) may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of Alpha, and/or persons and entities with relationships with Alpha. The Joint Lead Managers, their affiliates and/or related bodies corporate may also communicate independent investment recommendations, market colour or trading ideas and/or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire long and/or short positions in such assets, securities and instruments.

In connection with the Placement bookbuild, one or more investors may elect to acquire an economic interest in the New Shares (Economic Interest), instead of subscribing for or acquiring the legal or beneficial interest in those shares. The Joint Lead Managers (or their affiliates) may, for their own account, write derivative transactions with those investors relating to the New Shares to provide the Economic Interest, or otherwise acquire shares in Alpha in connection with the writing of such derivative transactions in the Placement bookbuild and/or the secondary market. As a result of such transactions, the Joint Lead Managers (or their affiliates) may be allocated, subscribe for or acquire New Shares or shares of Alpha in the Placement bookbuild and/or the secondary market, including to hedge those derivative transactions, as well as hold long or short positions in such shares. These transactions may, together with other shares in Alpha acquired by the Joint Lead Managers or their respective affiliates in connection with their ordinary course sales and trading, principal investing and other activities, result in the Joint Lead Managers or their affiliates disclosing a substantial holding and earning fees.

To the maximum extent permitted by law, Alpha and the Joint Lead Managers and each of their respective related bodies corporate and affiliates, and each of their respective officers, directors, partners, employees, agents and advisers (Limited Parties): (i) disclaim all duties, responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation, including for any indirect, incidental, consequential, special or economic loss or damage (including, without limitation, any loss of profit or anticipated profit, fines or penalties, loss of business or anticipated savings, loss of use, business interruption or loss of goodwill, bargain or opportunities); (ii) disclaim any obligations or undertaking to release any updates or revision to any information in this Presentation to reflect any change in expectations or assumptions; (iii) do not make any representation or warranty, (express or implied) as to the fairness, currency, accuracy, reliability, reasonableness or completeness of the information in this Presentation or that this Presentation contains all material information about Alpha or that a prospective investor and their professional advisers may reasonably require in evaluating a possible investment in Alpha, or likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement; and (iv) do not make any representation, warranty, assurance or guarantee (express or implied) that the information in this Presentation has been independently verified. Any information or representation in connection with the Placement not contained in the Presentation may not be relied upon as having been authorised by the Limited Parties.

The Joint Lead Manager Parties have not authorised, permitted or caused the issue, lodgement, submission, dispatch or provision of this Presentation and, for the avoidance of doubt, except for references to their names, none of them makes or purports to make any statements in this Presentation and there is no statement in this Presentation which is based on any statement by any of them. Further, the Joint Lead Manager Parties do not accept any fiduciary obligations to or relationship with you, any investor or potential investor in connection with the Equity Raising or otherwise. The Joint Lead Manager Parties make no recommendation as to whether any person should participate in the Equity Raising, nor do the Joint Lead Manager Parties make any representation, assurance or guarantee (express or implied) in connection with the repayment of capital or any particular rate of income or capital return on an investment in Alpha (including an investment in New Shares).

You acknowledge and agree that by accessing this Presentation:

- you expressly disclaim any fiduciary, agency, custodial or other legal relationship with the Joint Lead Manager Parties, and agree that you are responsible for making your own independent judgements as with respect of the Equity Raising or other matter arising in connection with this Presentation;
- to the maximum extent permitted by law, you undertake to not seek to bring any claim against the Joint Lead Manager Parties, or otherwise hold any of those parties liable in any respect, in connection with this Presentation or the Equity Raising;
- you warrant and agree that you have not relied on any statements made by the Joint Lead Manager Parties in relation to the Equity Raising; and
- with respect to the Joint Lead Managers and their affiliates and related bodies corporate, you understand and acknowledge that potential conflicts of interest, or a perception thereof, may arise as a result of the entry into of the transactions contemplated by Presentation and the other (potential) roles set out above.

You acknowledge and agree that determination of eligibility of investors for the purposes of the Equity Raising is determined by reference to a number of matters, including legal and/or regulatory requirements and the discretion of Alpha and the Joint Lead Managers, and each of the Limited Parties disclaim any duty or liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) to the maximum extent permitted by law in respect of that determination and the exercise or otherwise of that discretion. The Joint Lead Managers may rely on information provided by or on behalf of institutional investors in connection with managing, conducting and underwriting the Placement without having independently verified that information, and the Joint Lead Managers do not bear responsibility for the accuracy or completeness of that information.

For the avoidance of doubt, the Share Purchase Plan will not be underwritten.







## **ALPHA HPA: INTRODUCTION**

We are a technology led, specialty chemicals company

We make **ultra-high purity aluminium products** with a world first process which are:

CRITICAL MATERIALS FOR HIGH-TECHNOLOGY GROWTH SECTORS

**HIGH PURITY - HIGH MARGIN - LOW CARBON** 

Alpha is commercialising in 2 Stages as the

### **HPA FIRST PROJECT**

STAGE 1	SMALL SCALE COMMERCIAL PRODUCTION
STAGE 2	FINAL INVESTMENT DECISION FULL SCALE FACILITY



## **OVERVIEW**

### HPA First Project Stage 2: FID reached and equity raising

### **HPA FIRST PROJECT**

- The HPA First Project represents the twostaged commercialisation of the production of high purity aluminium materials
- The Stage 1, Precursor Production Facility has established successful production since November 2022
- FID<sup>1</sup> has now been reached for Stage 2, with the company committing to invest A\$553M, which includes A\$79m contingency<sup>2</sup>
- The DFS<sup>3</sup> outcomes highlight compelling economics for Stage 2, including
   ~A\$255M - A\$403M run rate EBITDA<sup>4</sup>

### **PROJECT FINANCING**

- Credit approved A\$320M facility (plus A\$80M cost overrun facility) secured from NAIF and EFA
- Fully underwritten institutional placement of A\$120M (before costs) and nonunderwritten Share Purchase Plan
- Government grants totalling ~A\$67M<sup>5</sup>
- Funds raised will be used to immediately commence Stage 2 project execution<sup>6</sup>

### **ALPHA'S ADVANTAGE**

- Technology de-risked with successful 16 month operation at Stage 1 PPF
- Established cost and carbon advantage over incumbent manufacturing processes
- Comprehensive marketing and technical qualification process has identified favourable pricing and growth markets:
   B2B<sup>7</sup> pricing protected from any index volatility
- Sales established across multiple markets and customer Letters of Intent (LOI) already in place across ~22% of the Stage 2 capacity
- High exposure to growing semiconductor, lithium-ion battery and LED lighting sectors

Note: 1. Financial Investment Decision. 2. The equity raising alongside the government debt facilities and government grants are part of a broader funding package Alpha is progressing to fully fund the HPA First Project Stage 2. 3. Definitive Feasibility Study. 4. Run rate EBITDA calculated when facility reaches 100% capacity (FY30). EBITDA assumed to be post Payroll tax and royalties. Range based on the Product Pricing Scenarios Alpha HPA Price Discovery Case and Independent Pricing Case as disclosed in the HPA First Project Stage 2 Commercialisation announcement on 20 May 2024. 5. \$4.5M of the Commonwealth Govt MMI-C grant will flow to Orica. 6. Regarding further project financing arrangements, Alpha has received non-solicited approaches for the provision of alternative and non-dilutive financing arrangements. Alpha will provide further project financing arrangements. Alpha will provide further project financing arrangements for Stage 2 in due course. 7. Business to business.

Alpha **HPA** 

### **INVESTMENT HIGHLIGHTS**

HPA First Project Stage 2 is expected to deliver compelling returns to investors driven by our technology's highly competitive unit cash costs and demand for multiple alumina products from our customers

### EXCEPTIONAL PRODUCTION PROFILE OF 10,430TPA<sup>1</sup>

Largest, single-site production of high purity aluminium materials globally

### ANNUAL, STEADY STATE PROJECT EBITDA OF A\$255M - A\$403M<sup>2</sup>

Margins driven by technology enabled cost base of A\$9.58/kg (US\$6.70/kg)

### HIGHLY CONSTRUCTIVE GLOBAL MACRO-THEMATICS

Government support for secure supply chains in fast growing technology sectors

### **A\$320M OF DEBT FUNDING**

Supportive, long term Australian Government loan facility 50:50 from NAIF and EFA

### FULLY UNDERWRITTEN INSTITUTIONAL PLACEMENT OF A\$120M

+ Share Purchase Plan (SPP) to enable retail participation

### **DE-RISKED PROCESS**

16 months of successful production from the Stage 1 Facility



Note: 1. 10,430tpa represents steady state operations, defined as post ramp-up (i.e. from FY30 onwards, noting the Company expects to be at an 87% throughput rate by FY28). 2. Revenue grows to A\$359m – A\$509m and EBITDA grows to A\$255m – A\$403m by FY30 reflecting 100% utilisation. EBITDA assumed to be post Payroll tax and royalties. Range based on the Product Pricing Scenarios Alpha HPA Price Discovery Case and Independent Pricing Case as disclosed in the HPA First Project Stage 2 Commercialisation announcement on 20 May 2024.

## **OUR PROCESS AND TECHNOLOGY**

Low cost, low energy process - highly cost/purity/carbon disruptive to incumbent processes which utilise aluminium metal feedstock



## **OUR PRODUCTS**

10,430tpa of bespoke products for high technology growth sectors<sup>1</sup>





We don't use aluminium metal as feedstock

Major reduction in process cost and carbon profile compared to incumbent process

We are the first global manufacturer of large volume, aluminium nitrates at world leading high purity (5N+)

Enables key lithium-ion battery safety technology

Enables ultra-high purity alumina and alumina tri-hydrate production (ATH or boehmite)



We recycle ~100% of our large volume reagents as a by-product



Highly flexible process with multiple product capability





Product mix optimised to meet customer demand





**ORICA:** YARWUN

**STAGE 1 PPF: IN PRODUCTION** 

HPA First Project Site Gladstone State Development Area 100% RENEWABLE ENERGY

## HPA FIRST PROJECT: GLADSTONE QLD

E BEELL

Alpha **HPA** 





### **STAGE1: IN PRODUCTION**

## **PROJECT LAYOUT**

- Strategically located in the Gladstone State Development Area and powered by 100% renewable energy as part of Alpha's commitment to decarbonisation
- Integrated Owners Team (IOT) execution model adopted for improved IP management and cost ownership ۲





## **COMPREHENSIVE GOVERNMENT SUPPORT**



Alpha staff hosting Prime Minister of Australia Anthony Albanese, Federal Minister of Resources Madeleine King, Queensland Premier Steven Miles, and Queensland Minister for Regional Development & Water Glenn Butcher





## **PRODUCT MARKETING**

Strong demand from customers driven by underlying sector growth, decarbonisation and supply chain de-risking



Stage 2: 10,430tpa Capacity

Active engagement and gualification sampling

with end-users representing ~300% coverage of

#### Note: 1. Up to 2,290tpa volume indication from LOIs signed (6 end-users to date).

## **MARKET OUTREACH AND PRICING**

- Extensive 4+ year global market outreach
- Detailed, technically driven understanding of market and applications
- Pricing obtained by interviews, sales, refined quotations and customer LOIs
- Comprehensive database of pricing available for Alpha's materials
- Alpha in product qualification testing for ~25,000tpa product demand
- B2B pricing protected from any index volatility





## **STRONG FINANCIAL METRICS**

Compelling HPA First Project Stage 2 financial metrics, ramping up to 87% throughput by FY28 and steady-state production in FY30

### HPA First Project Stage 2 Steady-state Financials

(does not include Alpha Sapphire)

Steady state (FY30) <sup>1</sup>	Units	Alpha HPA Price Discovery Case	Mid Case	Independent Pricing Case	
CapEx (includes \$79M contingency)		\$553M	\$553M	\$553M	
Production volume	tpa	10,430	10,430	10,430	
Weighted average product price	A\$/kg	\$34.44	\$42.34	\$48.77	
Revenue	A\$	\$359M	\$442M	\$509M	
Unit cash costs (after by-product credits) <sup>2</sup>		\$9.58	\$9.58	\$9.58	
EBITDA		\$255M	\$336M	\$403M	
Pre-tax free cash flows	A\$	\$251M	\$333M	\$399M	
HPAeq volume	tpa	6,850	6,850	6,850	
HPAeq price <sup>3</sup>	A\$/kg	\$52.44	\$64.47	\$74.26	
A\$359M – A\$509M Annual Revenue	<ul> <li><b>~71% - 79%</b> A\$251M − ,</li> <li>EBITDA Margin Pre-tax free ca</li> </ul>			·	

### First Project Stage 2



Production volume ramp up (tpa)

Note: 1: Revenue grows to A\$359m – A\$509m and EBITDA grows to A\$255m – A\$403m by FY30 reflecting 100% utilisation. EBITDA assumed to be post Payroll tax and royalties. Range based on the Product Pricing Scenarios Alpha HPA Price Discovery Case and Independent Pricing Case as disclosed in the HPA First Project Stage 2 Commercialisation announcement on 20 May 2024. 2. Operating Cost estimate does not include any potential impact of the Budget measures relating to critical minerals tax credits delivered as part of the Federal Budget on Tuesday 14 May 2024. 3. The sale of Al-Nitrates (high purity aluminium salt), which have lower aluminium content than high purity aluminas but a close to equivalent sales value by unit weight, provides a lift in HPAeq price received versus the HPA weighted average product price.

### **WE MAKE BATTERIES SAFER**

### ALPHA'S HIGH PURITY MATERIALS UNLOCK KEY LI-ION BATTERY SAFETY TECHNOLOGY



### **SUPPLYING HIGH POWER SEMICONDUCTORS**

### HPA and HPA precursors for:

- CMP polishing
- Thermal interface packaging •

HPA demand linked to high power semiconductors, particularly silicon-carbide (SiC)

Value of SiC Semiconductors in EV's (US\$M)



Source: Wolfspeed Investor Day 2022 Presentation

- First sales established
- Semiconductor sector LOI in place for up to 1,000tpa HPA



### **COST PROFILE**

Alpha's low energy and low carbon production process supports low cost, below incumbent peers

24 22 20 18 2021 16 \$/kg, 14 costs, 12 10 Production Japanese & South US\$6.70/kg 8 Sasol Chinese producers Korea producers 6 4 Alpha<sup>1</sup> 2 0 10,000 15,000 20,000 25,000 30,000 5,000 35,000 40,000 0 **Cumulative capacity, tonnes** 

HPA cost curve, current operations, 2021, US\$/kg1

### **4N+ HPA** production capacity is growing with demand<sup>1</sup>





### **ALPHA SAPPHIRE**

Forecast to deliver between U\$51.6M to U\$69.3M steady-state EBITDA from 100 sapphire growth units



	Annual EBITDA (USD) – post QIC Royalty <sup>1</sup>					
	Per single growth unit	Per 50 growth units	Per 100 growth units			
Base case	\$516,000	\$25,800,000	\$51,600,000			
High case	\$693,000	\$34,650,000	\$69,300,000			



### **ALPHA SAPPHIRE: ADDING DOWNSTREAM VALUE TO HPA**



- **Technology Disruption:** Access to new Ebner-Fametec Technology
- Supply Crunch: End-user desire to de-link from Russia-China production
- Demand Pull: Major new demand from micro-LED adoption



FAMETEC



## **EXPERIENCED LEADERSHIP TEAM**

Highly experienced Board and Executive Leadership Team, with a track record of project delivery



Norman Seckold Chairman 40+ years leading mineral development critical minerals companies



**Rimas Kairaitis** Managing Director 20+ years in mineral project development



Peter Nightingale Director 35+ years leading mineral development critical minerals companies



Craig Jones CFO 20+ years financing minerals and green energy globally



Rob Williamson Director & COO Mechanical engineer 25+ years in plant management and SX based start ups



**Tony Sgro** Non-Executive Director Chemical engineer with 45+ years in senior management positions



Dr Regan Crooks Non-Executive Director Chemical Engineer with 20+ years in commercialisation



Annie Liu Non-Executive Director Battery supply chain specialist with 20+ years leading teams through growth and scale up



Marghanita Johnson Non-Executive Director CEO of the Australian Aluminum Council since 2019 with 20+ years in sustainability management



**Richard Edwards** Company Secretary 20+ years in providing company secretarial and financial reporting services



## **PROJECT EXECUTION TIMETABLE**

Positioned to commence construction in Q3 2024

	2024		2025			2026				2027						
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Stage 1																
HPA production line ramp-up and production																
Stage 2																
Product marketing and customer contracts																
Financing																
Financial approval (FID)																
Front-end engineering																
Major contract award																
Long lead time orders																
Vendor manufacturing and supply																
Buildings and civil works																
Plant assembly																
Water commissioning																
Chemical commissioning																
Plant handover																
Production ramp up and start																



## **ORICA STRATEGIC INVESTMENT**

**RICA** 



- Technical and commercial validation via Orica due diligence and investment
- Investment builds upon binding arrangements to supply chemical reagents and offtake by-products at the HPA First Project
- $\checkmark$  Represents significant external endorsement of the capability, safety and operability of the process





### **ESG: INDEPENDENT CERTIFICATION**



## WORLD LEADING EMISSIONS

50-70% lower CO<sub>2</sub> emissions over incumbent (alkoxide) process



Independent emissions analysis by 🔁 Chain





# Financing

-



### **EQUITY RAISING OFFER SUMMARY**

Offer structure and size	<ul> <li>A\$120 million institutional placement (Placement) comprising:         <ul> <li>unconditional placement to raise approximately A\$64 million using the Company's Listing Rule 7.1 placement capacity through the issue of approximately 71 million new fully paid ordinary shares in Alpha (New Shares) (Tranche 1 Placement); and</li> <li>conditional placement to raise approximately A\$56 million through the issue of approximately 62 million New Shares, subject to shareholder approval that will be sought at a General Meeting expected to be held on or around Monday, 24 June 2024 (Tranche 2 Placement)</li> <li>In addition, Alpha is undertaking a non-underwritten Share Purchase Plan ("SPP")<sup>1</sup> to eligible shareholders in Australia and New Zealand</li> </ul> </li> </ul>
Placement Price	<ul> <li>All New Shares issued under the Placement at A\$0.90 per New Share (Placement Price)</li> <li>The Placement Price represents a 10.0% discount to the last closing price of A\$1.00 on Friday, 17 May 2024</li> </ul>
Ranking	All New Shares issued under the Placement and SPP will rank equally with Alpha's existing ordinary shares on issue
Cornerstone commitment	Pre-commitments have been received from Alpha's existing major shareholders including Orica Limited
Share Purchase Plan	<ul> <li>Eligible Alpha shareholders with a registered address in Australia or New Zealand will have the opportunity to apply for Alpha shares under a non-underwritten SPP</li> <li>Up to A\$30,000 of New Shares per eligible shareholder, free of any brokerage, commission or transaction costs</li> <li>The price for the SPP will be the lower of:         <ul> <li>The Placement Price; and</li> <li>A 2% discount to the 5-day VWAP of Alpha traded up to and including, the closing date of the SPP<sup>2</sup></li> </ul> </li> </ul>
Underwriting	<ul> <li>The Placement is fully underwritten</li> <li>Bell Potter Securities Limited and Macquarie Capital (Australia) Limited are acting as Joint Lead Managers (JLMs), Bookrunners and Underwriters</li> <li>The SPP is not underwritten</li> </ul>

## **SOURCES AND USES OF FUNDS**

### Project execution to commence immediately, with first production targeted for 1H FY27

- Funds raised under the Placement will be used to pay equity financing costs and immediately commence Stage 2 project execution, including:
  - finalising detailed engineering;
  - ordering long-lead items;
  - commencing civil and construction works; and
  - general working capital purposes
- Additional proceeds raised under the SPP will be used to immediately commence Stage 2 project execution
- The equity raising alongside the government debt facilities and government grants are part of a broader funding package Alpha is progressing to fully fund the HPA First Project Stage 2
- Alpha has received non-solicited approaches for the provision of alternative and non-dilutive financing arrangements from a number of parties, including advanced proposals for alternative financing to fund any further Stage 2 capital requirements

Sources	A\$m
Institutional Placement	120
SPP	Amount TBD
Total Sources	120 + SPP
Uses	A\$m
HPA First Project Stage 2 - Construction	110 + SPP
Working Capital	5
Est. Equity Financing costs	5
Total Uses	120 + SPP

Existing Funding Lines	A\$m
NAIF + EFA Facilities*	320
NAIF + EFA (COF)	80
MMI-C Grant**	45
IPP Grant	22
Total	467
* Subject to final conditions	
** 10% fund flow to Orica	

### **DEBT FUNDING SUMMARY AND KEY TERMS**

	Construc	tion facility	Cost Overrun Facility				
Lenders	The State of Queensland (as the lender of record for a commitment from NAIF)	Export Finance Australia (EFA)	NAIF/EFA 50:50				
Borrower	Solindo	Solindo Pty Limited (wholly owned subsidiary of Alpha HPA Limited)					
Sponsor	Alpha HPA Limited						
Limits	A\$160m	A\$80m					
Maturity date	11 years 5 years						
Other Conditions	<ul> <li>A final commitment is subject to conditions required under the Critical Minerals Facility, completion of all due diligence to the satisfaction of EFA and NAIF, execution of finance documentation and satisfaction of customary conditions precedent</li> <li>Drawdown is also subject to the company securing letters of intent and product qualification for an aggregate of 10ktpa reasonably aligned with the intended product and production profile</li> </ul>						

### **INDICATIVE EQUITY RAISING TIMELINE**

Key event	Date
Record Date for Eligibility to participate in SPP	7:00pm (AEST), Friday, 17 May 2024
Trading Halt lodged and announcement of Placement	Monday, 20 May 2024
Announcement of completion of Placement and trading halt lifted	Tuesday, 21 May 2024
Settlement of Tranche 1 Placement Shares	Thursday, 23 May 2024
Despatch of Notice of Meeting	Thursday, 23 May 2024
Allotment and commencement of trading of Tranche 1 Placement Shares	Friday, 24 May 2024
Despatch SPP offer documents and SPP Opening Date	Thursday, 28 May 2024
SPP Closing Date	Thursday, 13 June 2024
Announce results of the SPP and allotment of New Shares issued under the SPP	Thursday, 20 June 2024
Shares issued under the SPP commence trading	Friday, 21 June 2024
General Meeting to approve Tranche 2 Placement	Monday, 24 June 2024
Settlement of Tranche 2 Placement Shares	Wednesday, 26 June 2024
Allotment and commencement of trading of Tranche 2 Placement Shares	Thursday, 27 June 2024



The above timetable is indicative only and subject to change. The commencement of trading and quotation of New Shares issued under the Placement and SPP is subject to confirmation from ASX. Subject to the requirements of the Corporations Act, the ASX Listing Rules and other applicable rules, Alpha reserves the right to amend this timetable at any time, including extending the period for the SPP or accepting late applications, either generally or in particular cases, without notice. All times above are to Australian Eastern Standard Time.

Appendix A: Key Risks



### **KEY RISK DISCLOSURE**

This section discusses some of the key risks associated with an investment in shares in Alpha HPA Limited ("Shares"). There are a number of risk factors, specific to Alpha HPA Limited ("Company" or "Alpha") and of a general nature, which may affect the future operating and financial performance of Alpha, the industry in which it operates and the value of Alpha's Shares. Potential investors should consider whether the securities offered are a suitable investment having regard to their own personal investment objectives and financial circumstances and the risk factors set out below. Alpha has implemented appropriate strategies, actions, systems and safeguards for known risks; however, some are outside its control. While some common risk factors are set out below, it is not possible to produce an exhaustive list. The Alpha Directors recommend that potential investors consult their professional advisers before making any investment decisions.

	Alpha has entered into an underwriting agreement with the Joint Lead Managers to fully underwrite the Placement, subject to the terms and conditions of that agreement (the "Underwriting Agreement"). If certain conditions are not satisfied or certain events occur, then each Joint Lead Manager may terminate the Underwriting Agreement. The events which may trigger termination of the Underwriting Agreement are summarised in Appendix C of this Presentation.
Risks specific to the capital raising	The termination of the Underwriting Agreement would have an adverse impact on the amount of funds raised under the Placement and, if it were to occur, Alpha may need to take other steps to raise capital. Termination of the Underwriting Agreement could materially adversely affect Alpha's business, cash flow, financial condition and results of operations. Existing shareholders who do not participate in the Placement or the SPP will have their percentage shareholding diluted. Depending on the size of a shareholder's existing holding, participating shareholders may still be diluted even though they participate in the Placement or SPP depending on the number of New Shares allocated to them.
	The Placement is being undertaken in two tranches. The second tranche is subject to shareholder approval. There is a risk that the second tranche will not be able to proceed if the required shareholder approval is not obtained. There is also a risk that one or more investor under the second tranche may fail to fulfil its obligations and settle on the transaction once shareholder approval has been obtained. If either of these circumstances were to occur, it would have an adverse impact on the amount of funds raised under the Placement.



## **KEY RISK DISCLOSURE(continued)**

	There are general risks associated with investments in equity capital and shares in companies operating in the industries in which Alpha operates. Events may occur within or outside Australia, including in the jurisdictions where Alpha operates or plans on operating that could have an adverse effect on the global economy and fluctuations in Alpha's share price.
	There can be no guarantee that an active market for the Company's Shares will exist following the Placement. There may be relatively few potential buyers or sellers of Alpha Shares on the ASX at any given time.
	Share market conditions may affect the value of the Company's Shares irrespective of operational performance. Share market conditions are affected by many factors such as:
	general economic outlook;
	introduction of tax reform or other new legislation;
Risks associated with an	currency rates, interest rates and inflation rates;
investment in Shares	• commodity prices;
	change in investor sentiment towards particular market sectors;
	<ul> <li>the demand for, and supply of, capital;</li> </ul>
	<ul> <li>the potential impact of short selling;</li> </ul>
	• global or domestic pandemics; and
	• geopolitical instability, international hostilities or war and acts or terrorism in Australia and around the world, fires, floods, earthquakes, labour strikes, civil wars or natural disasters.
	Share prices may rise or fall and are subject to varied and unpredictable influences on the market for equities in general and stocks in the material sector in particular. Neither the Company nor its Directors warrant the future performance of Alpha or any return of an investment in Alpha.
Production and cost estimates	Whilst care has been taken in estimating the capital cost (including contingency), future operating costs and production profile for Stage 2 of the HPA First Project, the actual development cost, operating cost and production profile may vary from the estimates presented in the Definitive Feasibility Study. Any such variations could result in the Company not realising its operational and development plans or such plans costing more than expected or taking longer to realise than expected. Any of these outcomes could adversely affect the Company's futur financial position, operational performance and may impact the Company's ability to meet its debt financing obligations.
Pre-development stage	Stage 2 of the HPA First Project is at the pre-development stage. The prospects of the Company should be considered in light of the risks, expenses and difficulties frequently encountered by companies at this stage of development. The business of project development, project commissioning and production, by its nature, contains elements of significant risk with no guarantee of success. Ultimate and continuous success of these activities is dependent on many factors, such as equipment delivery or delivery of parts, and there can be no assurance the stage 2 of the HPA First Project will be brought into commercial production within the timeframes currently anticipated.

## **KEY RISK DISCLOSURE(continued)**

	Updates made to the layout of Stage 2 to accommodate additional product lines will require certain amendments to approvals and agreements from various authorities and third parties. The project execution schedule assumes the Company obtains all necessary approvals according to the anticipated timetable. Any delay in receiving appropriate approvals or reaching required agreements may adversely impact the Company's ability to bring Stage 2 of the HPA First Project to commercial production within the timeframes currently anticipated. Third-party supply agreements
Project approvals	The Company has a number of third-party supply agreements required for operations and commercial production at the HPA First Project. Key agreements include a supply agreement for bulk alumina-trihydrate feedstock with Rio Tinto and a supply and by-product return agreement for chemical reagents with Orica. There is no guarantee that any existing supplier agreements may be renewed on commercially reasonable terms, or at all. If, for any reason, Alpha fails to maintain strong relationships with these parties or damages its reputation with them, there would be a risk that these agreements may be breached, terminated, not renewed or renewed on less favourable terms. Any changes to third-party supply agreements, including agreements with Rio Tinto and Orica, may adversely impact the Company's financial and operating performance.
Environmental, social and governance risk	Stakeholders require proactive environmental, social and governance ("ESG") management. Failure to consider and adequately implement effective ESG measures and provide adequate disclosures may result in reduced investments, delays in approvals, regulatory intervention, community action, increased operating and insurance costs, damaged reputation and impacts to talent attraction and retention.
Climate risk	Climate change may cause certain physical and environmental risks that cannot be reasonably predicted by the Company. These risks include events such as increased severity of weather patterns and incidence of extreme weather events such as cyclones. Further, changes in laws and policies, including in relation to carbon pricing, greenhouse gas emissions and energy efficiency, may adversely impact operations.
Cyber risk	The Company relies on IT infrastructure and systems. The Company's IT infrastructure, systems and operations could be exposed to damage or interruption from system failures, computer viruses, cyber-attacks, power or telecommunication provider's failure or human error. Interruptions would impact the Company's ability to operate and could result in business interruption, loss of customers and revenue and damaged reputation.
Competition	The Company participates in the development of ultra-high purity aluminium and alumina products using its proprietary solvent extraction and refining technology. While the Company is of the view that there are currently no identified technologies which directly compete with its proprietary process, there are a range of other technologies currently available and in development which offer potential alternatives, in some of the products the Company produces. For example, high purity alumina from hydrochloric acid digestion of kaolin clay. It is conceivable, that in the future the market may be entered by globally focused competitors with significantly more access to capital and resources. Should any of the Company's competitors participate more aggressively on price, product, innovation or other means this could have a material adverse impact on the Company's business.
Personnel and labour risks	The development of ultra-high purity alumina products is bespoke and highly technical. Retention and recruitment of experienced personnel presents challenges given the lack of high purity alumina experience and expertise globally. Retaining qualified personnel is critical to the Company's success. If Alpha lost key personnel, it may adversely affect the Company's ability to conduct its business and accordingly, adversely affect the financial position and operational performance and prospects of Alpha. Similarly, as the Company's activities increase, it will require additional personnel. An inability to access and retain the services of required personnel may also adversely affect the financial position and prospects of the Company.
## **KEY RISK DISCLOSURE(continued)**

Work, health and safety	The Company strives to conduct its activities to the highest standard of work health and safety. Work health and safety, whilst always a risk, is at the forefront of operational focus to ensure it remains a top priority in all areas of the business. If there is any failure to comply with work, health and safety obligations, this may result in claims, fines, penalties, compensation claims against the Company and/or reputational damage.
Technological developments / disruption	The Company has developed a novel technology with limited operating history. There is no guarantee that the Company will successfully commission the full-scale Stage 2 HPA First Project or on time, and there is uncertainty surrounding the rate of growth and prospects for the Company.
Product pricing	The Company generates revenue primarily from the sale of high purity alumina, aluminium salts and other high purity aluminium products. The price of the inputs used to produce the products sold by the Company are generally determined following technical qualification with end-users. Accordingly pricing is set without reference to published price indices. The Company is in advanced technical qualification with multiple end-users and has established product sales with a number of end users. However, there is no guarantee that ongoing product qualification will be successful and the that the pricing and volume forecast set out in this investor presentation will be realized.
Foreign exchange rate	The Company is exposed to movements in foreign exchange rates (such as the USD), both transactional and translational, the impact of which cannot be reliably predicted. The financial information in the Company's financial statements is presented in Australian dollars. Some of the Company's revenue and expenses are transacted in foreign currencies. The Company has raised debt financing in Australian dollars. Foreign currency revenues and expenses are translated into Australian dollars for the purposes of presenting the consolidated Company group financial performance and position. An adverse movement in a relevant exchange rate may have an adverse impact on the Company's future reported financial performance.
Debt financing, liquidity	Alpha has received conditional approval for \$320 million in Project loan facilities and an \$80 million cost overrun facility in respect of Stage 2 of the HPA First Project (see Alpha's ASX announcement dated 17 April 2024). Alpha's ability to drawdown on the facility is subject to conditions required under the Critical Minerals Facility, completion of all due diligence to the satisfaction of EFA and NAIF, execution of finance documentation and satisfaction of customary conditions precedent. There is a risk that some of these conditions are not satisfied. Drawdown is also subject to the Company securing letters of intent and product qualification for an aggregate product volume of 10ktpa, reasonably aligned with the intended product and production profile. Any delay or inability to meet these conditions may result in an inability to drawn down on the Project loan facilities. An inability to drawn down on the Project loan facilities may result in delay or indefinite postponement of the development of Stage 2 of the HPA First Project unless alternative funding can be obtained.
and access to capital	Although the Company expects that the funds from the Placement, SPP and the Project loan facilities will be sufficient to commission Stage 2 of the HPA First Project (including allowances for contingency and cost overruns) and meet its business objectives, there can be no assurance that these objectives can be met without further financing or, if further financing is necessary, that financing can be obtained on favourable terms or at all. Any additional equity funding may be dilutive to shareholders. Any failure to raise additional funds if and when needed could have a material adverse effect on the Company's activities.
	Although Alpha has received non-solicited approaches for the provision of alternative and non-dilutive financing arrangements from a number of parties, there is no guarantee that these arrangements will eventuate or complete. If these arrangement do not complete, Alpha may need to raise further capital.
Delay in development of Stage 2 of the HPA First Project	There is a risk that there are delays in the development of Stage 2 of the HPA First Project. For example, if project approvals are not obtained on time or if there is a delay or inability to meet the conditions required for drawn down on the Project loan facilities, development of Stage 2 of the HPA First Project could be delayed which could adversely affect the Company's future financial position operational performance and/or reliance to shareholders.

## **KEY RISK DISCLOSURE(continued)**

Intellectual property	The Company's ability to leverage its innovations and know-how is contingent on its capacity to protect its intellectual property and associated improvements and developments. The Company may be required to incur significant expenses in establishing, protecting, and monitoring its intellectual property rights, including by engaging in litigation to enforce or vindicate its rights. There is a risk that third parties may make unauthorised use of, or successfully challenge Alpha's rights to use, those intellectual property rights. Unauthorised use of the Company's intellectual property by third parties, including potential or actual competitors of the Company, may have adverse effect on the Company.
Materials handling	The Company's business involves the controlled use of chemicals and is therefore subject to environmental and health and safety laws and regulations. There is a risk that the Company will not comply with these laws and regulations, or, despite its compliance, will nonetheless be exposed to industrial incidents relating to potentially hazardous materials. Such incidents may result in liability for contamination, compensation to individuals exposed to harm and remediation for damage caused. The Company may also be liable for fines imposed under applicable laws and regulations.
Force Majeure	Alpha's projects, now or in the future may be adversely affected by risks outside the control of Alpha, including labour unrest, civil disorder, war, subversive activities or sabotage, fires, floods, pandemics (i.e. Covid-19), explosions or other catastrophes, epidemics or quarantine restrictions.
Russia-Ukraine and Israel-Palestine conflict	The ongoing Russian-Ukraine and Israel-Palestine conflicts have had and will continue to have a significant impact on global economic markets. Although Alpha considers the current impact of the conflicts on Alpha to be limited, given that the conflicts are ongoing and volatile in nature, the future effect of the conflicts on Alpha is uncertain. The conflicts may have an adverse effect on the Company's share price or operations which will likely be out of Alpha's control.
General litigation and disputes	The Company is exposed to, and may from time to time be involved in, potential legal and other claims or disputes from time to time in the course of its businesses with its contractors, shareholders, sub-contractors, employees, former employees, government agencies or regulators, end-consumers, customers, vendors or suppliers and other parties. Such legal and other claims or disputes may include (but are not limited to) potential class actions, contractual disputes, property damage claims, personal liability claims, products and services liability claims, or contractual and statutory penalties for failure to fulfil statutory and contractual obligations in relation to the quality of products and services, as well as governmental enquiries and investigations with respect to its operations. Litigation and disputes can be costly, including amounts payable in respect of judgments and settlements made against, or agreed to by, the Company. They can also take up significant time and attention from management and the Board. Further, depending on the outcome of any litigation, Alpha may be required to comply with broad court orders, including compliance orders, enforcement orders or otherwise pay money such as damages, fines, penalties or legal costs. Accordingly, the Company's involvement in litigation and disputes could have an adverse impact on its financial position and performance. In addition, regulatory actions, disputes and other legal claims may result in fines, penalties and other sanctions, as well as other costs and expenses (including adviser costs in defending or responding to the relevant claim and settlement payments).
Unforeseen risk	There may be other risks of which Alpha is unaware at the time of this Presentation which may impact Alpha, its operations and / or the valuation and performance of its shares. The key risks disclosed in this Presentation ought not to be taken as exhaustive of the risks faced by Alpha or by investors in Alpha. The above risks and others not specifically referred to above may in the future materially affect Alpha, its financial performance or the value of its shares.

# Appendix B: International Offer Restrictions



#### **INTERNATIONAL OFFER RESTRICTIONS**

This document does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted below.

Bermuda	No offer or invitation to subscribe for New Shares may be made to the public in Bermuda or in any manner that would constitute engaging in business in or from within Bermuda. In addition, no invitation is being made to persons resident in Bermuda for exchange control purposes to subscribe for New Shares.
	This document constitutes an offering of New Shares only in the Provinces of British Columbia, Ontario and Quebec (the "Provinces"), only to persons to whom New Shares may be lawfully distributed in the Provinces, and only by persons permitted to sell such securities. This document is not a prospectus, an advertisement or a public offering of securities in the Provinces. This document may only be distributed in the Provinces to persons who are "accredited investors" within the meaning of National Instrument 45-106 – Prospectus Exemptions, of the Canadian Securities Administrators.
	No securities commission or authority in the Provinces has reviewed or in any way passed upon this document, the merits of the New Shares or the offering of the New Shares and any representation to the contrary is an offence.
	No prospectus has been, or will be, filed in the Provinces with respect to the offering of New Shares or the resale of such securities. Any person in the Provinces lawfully participating in the offer will not receive the information, legal rights or protections that would be afforded had a prospectus been filed and receipted by the securities regulator in the applicable Province. Furthermore, any resale of the New Shares in the Provinces must be made in accordance with applicable Canadian securities laws. While such resale restrictions generally do not apply to a first trade in a security of a foreign, non-Canadian reporting issuer that is made through an exchange or market outside Canada, Canadian purchasers should seek legal advice prior to any resale of the New Shares.
Canada (British Columbia, Ontario and Quebec provinces)	The Company as well as its directors and officers may be located outside Canada and, as a result, it may not be possible for purchasers to effect service of process within Canada upon the Company or its directors or officers. All or a substantial portion of the assets of the Company and such persons may be located outside Canada and, as a result, it may not be possible to satisfy a judgment against the Company or such persons in Canada or to enforce a judgment obtained in Canadian courts against the Company or such persons outside Canada.
·····	Any financial information contained in this document has been prepared in accordance with Australian Accounting Standards and also comply with International Financial Reporting Standards and also comply with International Accounting Standards Board. Unless stated otherwise, all dollar amounts contained in this document are in Australian dollars.
	Statutory rights of action for damages and rescission. Securities legislation in certain Provinces may provide a purchaser with remedies for rescission or damages if an offering memorandum contains a misrepresentation, provided the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's Province. A purchaser may refer to any applicable provision of the securities legislation of the purchaser's Province for particulars of these rights or consult with a legal adviser.
	Certain Canadian income tax considerations. Prospective purchasers of the New Shares should consult their own tax adviser with respect to any taxes payable in connection with the acquisition, holding or disposition of the New Shares as there are Canadian tax implications for investors in the Provinces.
	Language of documents in Canada. Upon receipt of this document, each investor in Canada hereby confirms that it has expressly requested that all documents evidencing or relating in any way to the sale of the New Shares (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only. Par la réception de ce document, chaque investisseur canadien confirme par les présentes qu'il a expressément exigé que tous les documents faisant foi ou se rapportant de quelque manière que ce soit à la vente des valeurs mobilières décrites aux présentes (incluant, pour plus de certitude, toute confirmation d'achat ou tout avis) soient rédigés en anglais seulement.

Cayman Islands	No offer or invitation to subscribe for New Shares may be made to the public in the Cayman Islands or in any manner that would constitute carrying on business in the Cayman Islands.
European Union	This document has not been, and will not be, registered with or approved by any securities regulator in the European Union. Accordingly, this document may not be made available, nor may the New Shares be offered for sale, in the European Union except in circumstances that do not require a prospectus under Article 1(4) of Regulation (EU) 2017/1129 of the European Parliament and the Council of the European Union (the "Prospectus Regulation").
(excluding Austria)	In accordance with Article 1(4)(a) of the Prospectus Regulation, an offer of New Shares in the European Union is limited to persons who are "qualified investors" (as defined in Article 2(e) of the Prospectus Regulation).
	WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the "SFO"). Accordingly, this document may not be distributed, and the New Shares may not be offered or sold, in Hong Kong other than to "professional investors" (as defined in the SFO and any rules made under that ordinance).
Hong Kong	No advertisement, invitation or document relating to the New Shares has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Shares that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted New Shares may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities.
	The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this document, you should obtain independent professional advice.
	This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the "FMC Act").
	The New Shares are not being offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) other than to a person who:
	• is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
New Zealand	meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
	is large within the meaning of clause 39 of Schedule 1 of the FMC Act;
	is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or
	• is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.



Norway	This document has not been approved by, or registered with, any Norwegian securities regulator under the Norwegian Securities Trading Act of 29 June 2007 no. 75. Accordingly, this document shall not be deemed to constitute an offer to the public in Norway within the meaning of the Norwegian Securities Trading Act. The New Shares may not be offered or sold, directly or indirectly, in Norway except to "professional clients" (as defined in the Norwegian Securities Trading Act).
Singapore	This document and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of New Shares, may not be issued, circulated or distributed, nor may the New Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the "SFA") or another exemption under the SFA.
engapore	This document has been given to you on the basis that you are an "institutional investor" or an "accredited investor" (as such terms are defined in the SFA). If you are not such an investor, please return this document immediately. You may not forward or circulate this document to any other person in Singapore.
	Any offer is not made to you with a view to the New Shares being subsequently offered for sale to any other party in Singapore. On-sale restrictions in Singapore may be applicable to investors who acquire New Shares. As such, investors are advised to acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly.
	The New Shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange or on any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the New Shares constitutes a prospectus or a similar notice, as such terms are understood under art. 35 of the Swiss Financial Services Act or the listing rules of any stock exchange or regulated trading facility in Switzerland.
Switzerland	No offering or marketing material relating to the New Shares has been, nor will be, filed with or approved by any Swiss regulatory authority or authorised review body. In particular, this document will not be filed with, and the offer of New Shares will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA).
	Neither this document nor any other offering or marketing material relating to the New Shares may be publicly distributed or otherwise made publicly available in Switzerland. The New Shares will only be offered to investors who qualify as "professional clients" (as defined in the Swiss Financial Services Act). This document is personal to the recipient and not for general circulation in Switzerland.



	This document does not constitute a public offer of securities in the United Arab Emirates and the New Shares may not be offered or sold, directly or indirectly, to the public in the UAE. Neither this document nor the New Shares have been approved by the Securities and Commodities Authority ("SCA") or any other authority in the UAE.
United Arab Emirates	No marketing of the New Shares has been, or will be, made from within the UAE other than in compliance with the laws of the UAE and no subscription for any securities may be consummated within the UAE. This document may be distributed in the UAE only to "professional investors" (as defined in the SCA Board of Directors' Decision No.13/RM of 2021, as amended).
	No offer of New Shares will be made to, and no subscription for New Shares will be permitted from, any person in the Abu Dhabi Global Market or the Dubai International Financial Centre.
	Neither this document nor any other document relating to the offer has been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended ("FSMA")) has been published or is intended to be published in respect of the New Shares.
	The New Shares may not be offered or sold in the United Kingdom by means of this document or any other document, except in circumstances that do not require the publication of a prospectus under section 86(1) of the FSMA. This document is issued on a confidential basis in the United Kingdom to "qualified investors" within the meaning of Article 2(e) of the UK Prospectus Regulation. This document may not be distributed or reproduced, in whole or in part, nor may its contents be disclosed by recipients, to any other person in the United Kingdom.
United Kingdom	Any invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) received in connection with the issue or sale of the New Shares has only been communicated or caused to be communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of the FSMA does not apply to the Company.
	In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 ("FPO"), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated ("relevant persons"). The investment to which this document relates is available only to relevant persons. Any person who is not a relevant person should not act or rely on this document.



United States		This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.
	United States	The New Shares may be offered and sold in the United States only to:
		• "qualified institutional buyers" (as defined in Rule 144A under the US Securities Act); and
		• dealers or other professional fiduciaries organized or incorporated in the United States that are acting for a discretionary or similar account (other than an estate or trust) held for the benefit or account of persons that are not US persons and for which they exercise investment discretion, within the meaning of Rule 902(k)(2)(i) of Regulation S under the US Securities Act.

# Appendix C: Placement Agreement Summary



#### **PLACEMENT AGREEMENT SUMMARY**

Alpha has entered into a placement agreement with the JLMs in respect of the Placement (Placement Agreement). The Placement Agreement contains customary representations and warranties and indemnities in favour of the JLMs. Details of the fees payable to the JLM are included in the Appendix 3B released to the ASX on the date of this document. A JLM may terminate its obligations under the Placement Agreement at any time prior to 4pm on the settlement date of the Tranche 2 Placement, where:

- a) any one or more of the following events occur:
  - i. Alpha fails to perform or observe any of its obligations (including, for the avoidance of doubt, undertakings) under the Placement Agreement;
  - ii. any representation or warranty made or given by Alpha in the Placement Agreement is or becomes misleading or deceptive, or is not true or correct;
  - iii. a certificate which is required to be furnished by Alpha under the Placement Agreement when given is untrue, incorrect or misleading or deceptive;
  - iv. there is introduced into Australia or any State or Territory of Australia a law, or any new regulation is made under any law, or a governmental authority adopts a policy which affects or regulates the Placement or its settlement or the issue or taxation treatment of the Placement shares, or there is any official announcement on behalf of the Government of Australia or any State or Territory of Australia or a governmental authority that such a law or regulation will be introduced or policy adopted (as the case may be);
  - v. a change to the CEO or the CFO or the board of directors of Alpha occurs;
  - vi. there is an outbreak or a major escalation of hostilities (whether war is declared or not) involving any one or more of Australia, New Zealand, the United Kingdom, any member state of the European Union, the United States or China or the declaration by any of these countries of a national emergency or war, or a significant terrorist attack is perpetrated in any of those countries or any diplomatic, military, commercial or political establishment of any of these countries;
  - vii. any of the following occurs (i) a general moratorium on commercial banking activities in Australia, New Zealand, the United Kingdom, the United States or China is declared by the relevant central banking authority in those countries, or there is a disruption in commercial banking or security settlement or clearance services in any of those countries; (ii) trading in all securities quoted or listed on ASX, the London Stock Exchange, Hong Kong Stock Exchange or New York Stock Exchange is suspended or limited in a material respect; or (iii) any adverse change or disruption to the existing financial markets, political or economic conditions of Australia, New Zealand the United Kingdom, the United States or China, or any change in national or international political, financial or economic conditions; or

viii. any adverse change occurs in the assets, liabilities, financial position or performance, profits, losses or prospects of Alpha or any of its related bodies corporate (each a member of the Group) (insofar as the position in relation to an entity in the Group affects the overall position of Alpha), including any adverse change in the assets, liabilities, financial position or performance, profits, losses or prospects of the Group from those respectively disclosed in the ASX announcement, this document and any other documents issued or published by or on behalf of (with its prior approval) Alpha in respect of, or relating to, the Placement (each a Placement Document);

and the JLM has reasonable grounds to believe and does believe that: (a) the event has had, or is likely to have, a materially adverse effect on the outcome or success or settlement of the Placement or on the ability of the JLM to market or promote or settle the Placement; or (b) could give rise to or result in a contravention or involvement in a contravention by the JLM or one of its affiliates of, or liability for the JLM or one of its affiliates under, the Corporations Act or any applicable law;

- shareholder approval is not obtained by Alpha on the date that is two business days after the date specified in the timetable, without the prior approval of the JLMs;
- c) any debt document (being a credit approval in respect of the \$320m construction facility and/or the \$80m overrun facility from NAIF and EFA) is breached in a material respect, terminated (or becomes terminable, void, voidable or unenforceable), rescinded or altered or amended without the prior written consent of the JLMs, or a condition precedent to which any debt document is subject has, in the reasonable opinion of the JLMs, become impossible to be satisfied by its due date (unless waived) or any event occurs which gives a lender or financier under a debt document the right to accelerate or require repayment of the debt or financing thereunder;
- d) ASIC makes an application for an under Part 9.5 of the Corporations Act in relation to the Placement or the Notice of Meeting; commences, or gives notice of its intention to commence, any investigation or hearing under Part 3 of the Australian Securities and Investments Commission Act in relation to the Placement or the Notice of Meeting; or otherwise issues proceedings in relation to the Placement or the Notice of Meeting or commences any formal inquiry or investigation into the Placement;
- e) either as at the close of trading on any trading day between the opening of the bookbuild and the Tranche 1
  Placement settlement date (each inclusive), the S&P/ASX 200 Index is 10% or more below its level as at the close of trading on the last trading day immediately prior to the date of the Placement Agreement or as at the close of trading on any trading day between the Tranche 1 Placement settlement date and the Tranche 2
  Placement settlement date (each inclusive), the S&P/ASX 200 Index is 15% or more below its level as at the close of trading on the last trading day immediately prior to the date of the Placement Agreement;

#### **PLACEMENT AGREEMENT SUMMARY(continued)**

- ASX announces that Alpha's shares will be delisted, removed from quotation, withdrawn from admission to trading status or suspended from quotation (which, for the avoidance of doubt, does not include a trading halt requested to facilitate the Placement);
- g) ASX notifies Alpha or a JLM that unconditional approval (or approval conditional only on customary conditions which are acceptable to the JLMs, acting reasonably) will not be granted to the official quotation of all of the Tranche 1 Placement shares or the Tranche 2 Placement shares on ASX;
- h) Alpha withdraws the Placement or any component of the Placement;
- any event specified in the Timetable (i) before and up to the Tranche 1 Allotment Date, is delayed for more than one Business Day; or (ii) after the Tranche 1 Allotment Date, is delayed for more than two Business Days, in each case, without the prior approval of the Joint Lead Managers;
- j) a certificate required to by furnished by Alpha under the Placement Agreement is not furnished when required;
- a Placement Document includes content that is untrue, inaccurate, misleading or deceptive or likely to mislead or deceive (whether by inclusion or omission);
- a member of the Group that is material in the context of the business of the Group is or becomes insolvent or there is an act or omission which is likely to result in such member of the Group becoming insolvent;
- m) a director of Alpha is charged with an indictable offence or any regulatory body commences any public action against the director or announces that it intends to take any such action; or is disqualified from managing a corporation under sections 206B, 206C, 206D, 206E, 206F or 206G of the Corporations Act;
- n) it becomes illegal for a JLM to satisfy an obligation under the Placement Agreement; or
- o) Alpha or any of its directors or officers (as that term is defined in the Corporations Act) engage in any fraudulent conduct or activity whether or not in connection with the Placement.



## Thank You

Rimas Kairaitis Managing Director <u>rkairaitis@alphahpa.com.au</u> +61 408 414 474

**Robert Williamson** Director and COO

rwilliamson@alphahpa.com.au +61 407 125 176

**Rob Lord** Investor Relations

rlord@alphahpa.com.au +61 400 008 553

Cameron Peacock Business Development

cpeacock@alphahpa.com.au +61 439 908 732

<u>alphahpa.com.au</u>



